A PhaseⅠ, Randomized, Observer-blinded, Active Comparator, First-in-human Clinical Trial to Evaluate Safety and Tolerability of Herpes Zoster Vaccine EuHZV in Healthy Adults Aged 50 to 69 Years
Latest Information Update: 29 Apr 2025
At a glance
- Drugs EuHZV (Primary)
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Adverse reactions; First in man
- Sponsors EuBiologics
Most Recent Events
- 24 Apr 2025 Planned primary completion date changed from 1 May 2025 to 31 Jul 2025.
- 24 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2024 Status changed from not yet recruiting to recruiting.